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1. Introduction
One of the few facts all those involved in kidney allografting agreed on
almost from the beginning is that matching for the HLA System plays an
overriding role when donor and recipient are siblings. It was one of the
fundamental observations that identified the HLA system as the major
histocompatibility complex (MHC).
Although the HLA system is extremely complex, its polymorphism
can be considered finite. This implies that unrelated individuals exist
who share one or two HLA haplotypes. In the parent-child combination,
matching for the unrelated haplotype was shown to improve kidney-graft
survival (van Rood et al., 1967). On the basis of this observation, it was
suggested that to overcome the difficulty of finding good matches between
unrelated individuals, a large pool of patients awaiting kidney transplan-
tation should be created (van Rood, 1967). Whenever a kidney donor
becomes available, the best-matched recipient is selected from the pool.
Although this proposal, which led to unique international and inter-
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center medical collaboration, was received well, it took ten years before
the consensus was reached that HLA matching was helpful m the
unrelated donor-recipient combinations {Transplantation Proceedings,
1977). In retrospect, this delay can be explained by the following
considerations
1. Many of the early studies had, because of the extreme polymorph-
lsm of HLA, far too few "good" matches—i.e., HLA-A- and-5-
identical matches—to allow for a meanmgful Interpretation of the
data
2. The influence of hnkage dysequilibnum was msufficiently taken
into account in most studies.
3 In the unrelated donor-recipient combination, where complete
HLA identity IS rare, lf it occurs at all, helper or suppressor
mechanisms, or both, can be activated that make a simphstic
Interpretation of the number of HLA-A and -B mismatches
redundant.
That HLA-A and -B matching does improve kidney allografting is
illustrated by Fig. 1, which presents the results obtamed in the organ-
exchange organizaüon Eurotransplant in the penod 1972-1977 and con-
cerns over 3000 first cadavenc transplants (Persijn et al , 1979). The data
show that 5 years after transplantaüon, grafts with no HLA-A and -B
imsmatches do over 15% better than grafts mismatched for three or four
anügens. The difference is statistically significant from 6 months post-
transplant onward and meanmgful both for the patient and in the context
of the cost-benefit aspects of the treatment of end-stage renal failure.
Two further pomts can be deduced from Fig. 1 as well. The first is
that about one third of the transplants fail withm the first 3-6 months
after transplantaüon, and the second is that although the grafts mis-
matched for three or four HLA-A and -B anügens do on the average less
well tban those that were better matched, some of these three- to foui-
antigen-mismatched grafts do quite well even after 5 years In other
words, even a good HLA-A and -B match is no guarantee of good
funcüon, and by contrast, good graft function can occur vis-ä-vis a very
poor HLA match It is both of great theoretical importance and of great
practical importance to understand the mechanism by which these
mismatched grafts are able to survive
Recently, several variables have been identified that apart from
HLA-A and -B matching per se are able to significantly influence kidney
graft survival. We will discuss three of these Blood transfusion and
HLA-DR matching have a graft-protecüng effect, while lncompaübihty
for MHC-restncted and MHC-nonrestncted non-HLA anügens can lm-
pair graft survival.
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Figure 1. Kidney-graft survival of over 3000 consecutive transplants performed in collab-
oration with the Eurotransplant organ-exchange organization. Note that after 6 months,
there IS an 8% difference, and after 60 months a 15% difference, between the best- and
poorest-matched grafts. From Persijn et al. (1979).
2. Blood Transfusion
Opelz et al. (1973) were the first to present significant evidence not
only that blood transfusion can cause immunization, which endangers
graft survival, but also that it can prolong graft survival. Their observa-
tion has been confirmed by most workers, including our own group
(Persijn et al., 1977). Furthermore, a randomized prospective study in
rhesus monkeys that received five blood transfusions over a 3-month
period prior to transplantation and Standard immunosuppression after
transplantation showed a significant fourfold Prolongation of graft surviv-
al (Fig. 2) (van Es et al., 1977).
In Leiden, a retrospective study by van Hooff et al. (1976) showed
that patients who had received one blood transfusion appeared to do
better than patients who had received none. Next, Persijn et al. (1979)
evaluated the role of the number of blood transfusions in kidney-graft
survival in 895 patients who had received a kidney transplant between
January 1, 1967, and March 1, 1977. The transfusion history was checked
by scrutinizing the relevant documents (e.g., medical history, blood bank
files, hemodialysis reports) and by personal Interviews with the patients
or their relatives or both. For female patients, the number of pregnancies
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Figure 2 Influence of blood transfusion on
kidney allograft survival in unrelated rhesus
monkeys Solid black bars depict individual
survival times, shaded areas indicate the
mean survival time(MST) per expenmen
tal group Immunosuppression consisted of
azathiopnne (4 mg/kg) and prednisolone (2
mg/kg), given on alternate days Five blood
transfusions were given at biweekly inter
vals Transplantation was performed 11-23
days after the last transfusion From van Es
et al (1977)
and abortions was recorded. In this way, these authors found 68 male
and 6 female patients who had never been transfused or been pregnant
before transplantaüon. None of them had preformed leukocyte antibodies
in their serum Similarly, 27 male and 3 never-pregnant female patients
were identified who had received only a Single blood transfusion, a third
of them 1 year or more before transplantation. Some of these patients
remembered the exact date of transfusion, and this was checked and
confirmed in the blood bank records. None of these patients had
detectable antileukocyte antibodies in their sera. The composition of the
transfusate (e.g., whole blood, washed erythrocytes, filtered blood) was
not taken into account because accurate Information on this was not
available. All patients in this analysis, except one patient in the nontrans-
fused group, had received blood transfusions dunng transplantation
varying from 1 to more than 5 units. As can be seen in Fig. 3, the
patients who had received one blood transfusion did extremely well (80%
graft survival at 6 months after transplantation), while those who had
received no blood transfusion did very poorly indeed.
On the basis of these findings, a prospective tnal was started in
Holland in which lt was planned to compare the graft-protecting effect of
one pretransplant transfusion of leukocyte-poor blood with three such
transfusions. The precise way in which the blood was to be prepared
was not specified. Most centers gave "washed" leukocyte-poor blood,
but a few used cotton-wool-filtered blood, which for all pracücal purposes
IS leukocyte-free (Diepenhorst et al., 1972) As IS shown in Fig. 3, this
prospective study confirmed the retrospective study with respect to the
graft-protecting effect of one transfusion of leukocyte-poor blood. In
contrast, the patients transfused with cotton-wool-filtered leukocyte-free
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Figure 3. Graft survival in relation to a single pretransplant blood transfusion. Only
transfusions of leukocyte-poor blood had a graft-protecting effect. From Persijn et al.
(1978).
blood did as poorly as the nontransfused patients. We conclude from
these data that a small amount of buffycoat cells given once before
transplantation induces significant graft protection and that buffycoat-
free erythrocytes will not do so. Others have suggested that peroperative
blood transfusions without preoperative ones can cause graft facilitation
(Stiller et al., 1978). During the last two years, almost all peroperative
blood transfusions to the patients shown in Fig. 3 have been leukocyte-
free. However, before that date, leukocyte-poor blood was often given.
Its effect on graft survival is under study. Because of the very poor
overall graft survival in the group of patients who received no blood
transfusions before transplantation, it appears unlikely to us that per-
operative blood transfusions with leukocyte-poor blood are as effective
as preoperative ones.
On two points, our findings are at variance with those of others.
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First, although almost all authors agree that patients who had received
pretransplant blood transfusions do better than those who did not, most
centers find that graft survival in the nontransfused group is not 20-30%
as we observed (Fig. 3), but 40-60% at 1 year (Morris et al., 1978; Opelz
and Terasaki, 1978). We have no good explanation for this discrepancy.
Inadequate inventorying of the blood-transfusion history might be an
explanation for some but not for all studies. The poorer graft survival in
our nontransfused-patient group is unlikely to be due to poorer HLA
matches as compared to the other studies. This discrepancy thus focuses
our attention on yet another unknown variable determining the outcome
of kidney transplantation.
Second, another discrepancy lies in the number of blood transfusions
given. Although some centers (Morris, personal communication) have
confirmed our Unding that one blood transfusion protects graft survival,
others have not (Opelz and Terasaki, 1978). This is another unexplained
discrepancy. Preliminary findings from our group suggest that one blood
transfusion is especially effective in the group of patients who received
a one-DR-antigen-mismatched graft (see below). Because Opelz's patient
material is racially more heterogeneous than the Dutch material, this
observation might be relevant.
The mechanism by which blood transfusion protects graft survival
is unknown. In all probability, this mechanism is different when many
blood transfusions have been given as compared to the Situation in which
only one or a few were given. Many blood transfusions will induce
cytotoxic HLA antibodies in many patients. Those who do not form
cytotoxic HLA-Α and -B antibodies are so-called "nonresponders."
Graft survival in this group is known to be good. The term nonresponder
is a misnomer, because these patients do form antibodies (anti-HLA-DR
or other) that might be enhancing (Iwaki et al., 1978; Thompson et al.,
1976). Those who have formed cytotoxic anti-HLA antibodies will
receive kidneys from donors who lack the corresponding antigens. It is-
assumed but not proven that such recipients cannot easily form immunity
against other HLA antigens, and thus incompatibility for these will not
influence graft survival.
This selection phenomenon cannot play a role when only one blooc
transfusion has been given because in such cases, no antibodies or onl;
weak antibodies in only a few recipients are formed. Whether the
improved graft survival is due to the induetion of suppressor cells, broad
reacting enhancing antibodies, or another mechanism is as yet unclear
In conclusion, almost everybody agrees that blood transfusion cai
improve graft survival, but there is no agreement on the optimal numbe
of blood transfusions to be given, the time interval between
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transfusion and transplantation, or even the way in which the blood
should be prepared.
3. HLA-DR Matching
Almost from the beginning of clinical kidney allografting, evidence
has been accumulating that indicated that a low or negative mixed-
lymphocyte culture (MLC) test was indicative for good transplant prog-
nosis. This was in itself an important impetus to develop methods of
typing the HLA-D determinants, which are the strengest Stimulus in the
MLC test (Transplantation Proceedings, 1977). The methods all used
the basic MLC test or variants of it. However, because the MLC test is
so time-consuming, it is suitable only for selection of living donor-
recipient pairs.
Thus, a method was developed that would aüow rapid identification
of //LA-Z)-identical donor-recipient pairs and that could be applied to
cadaveric donors. Α systematic search for antibodies that could recognize
the HLA-D determinants was begun. This effort was successful, and
antibodies were identified that allowed the recognition of HLA-D antigens
or determinants closely linked to them (Fig. 4) (van Rood et al., 1978).
The main topic of the 7th Histocompatibility Workshop was the recog-
nition of these so-called "HLA-DR determinants" (Histocompatibility
Testing 1977).
To assess the importance of HLA-DR matching in kidney transplan-
tation, DR typing was performed on peripheral-blood cells of the recip-
ient and frozen spieen cells from the corresponding kidney donor (Persijn
et al., 1978). Figure 5A shows the influence of DR matching alone and
Fig. 5B the influence of DR matching combined with (partial) matching
for the HLA-A and -B antigens. Although the numbers are small and this
is a retrospective study, the study strongly suggests that (1) even
matching for one HLA-DR determinant can significantly reduce early
graft loss (cf. Fig. 1); and (2) matching for HLA-DR combined with
partial matching for the HLA-A and -B antigens might further improve
prognosis; and (3) matching for both DR antigens appears to result in
good graft survival as well, but here the numbers are too small for
meaningful conclusions.
Other groups have done similar studies. Α summary of the total of
the published European data is presented in Table 1 (Ting and Morris,
1978; Martins-da-Silva et al, 1978; Albrechtsen et al., 1978). It is clear
that although the number of //LA-Di?-identical grafts is small, they give
the highest percentage of functioning grafts in all series, and that the
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Figure 4 Results of testing of lymphocytes of 60 unrelated donors by homozygous typing
cells (HTC) and pnmed lymphocyte typing (PLT) recogmzing the HLA D specrficities
HLA Dwl-8 Positive results are mdicated by the stippled bars The same panel was tested
by sera recogmzing HLA DRwl-7 and HLA WIA8 Positive results are mdicated by the
hdtched bars Note the excellent agreement of the results obtained with cellular (HTC and
PLT) and serological (HLA DR serology) techmques foi determinants 1, 2, 3, and 7 The
number of possrble tnplets IS only one for HLA DR, suggesting that HLA DR determinants
might be coded for by one locus
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percentage of functioning grafts in the two-DR-antigens-mismatched
group is the lowest. Problems arise with the one-DR-antigen-mismatched
group because it is often imclear from publications of others whether
these include potential incompatibilities or not (e.g., an HLA-DRwl/—
donor transplanted onto an HLA-DRwl/2 recipient). With this restriction,
the available data show that in the majority of transplants performed in
Europe, matching for two and also for one HLA-DR antigen improves
graft survival significantly. The improvement by matching for two HLA-
DR determinants was expected because earlier studies had shown that a
low or negative MLC test between parent-child or unrelated donor-
recipient pairs improved graft survival (Jeannet, 1970; Hamburger et al.,
1971; Cochrum et al, 1973). Although not all HLA-D- or -£>/?-identical
combinations lead to a negative or low MLC test, the majority do
°o GRAFT
SURVIVAL
90
80
60
50
NUMBER OF
MISMATCHES
6 12 18
FOIIOW-UP TIME (MO)
Figure 5A. Kidney-graft survival and matching for HLA-DR antigens alone. The top curve
represents grafts with one mismatch at the DR locus, the middle curve, ßÄ-identical
grafts, the bottom curve, grafts with two mismatches at the DR locus. The figures above
the curves are the numbers of grafts at nsk.
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Figure 5B Kidney-graft survival and matching for HLA A, -B, and DR anügens The top
curve represents £>Ä-identical grafts with one or fewer mismatches at theA orB locus, the
middle curve, grafts with one or fewer mismatches at the Α or Β locus and one mismatch
at DR, the bottom curve, other grafts From Persyn et al (1978)
TABLE 1 DR Matching in Europea
Source
Eurotransplant
Geneva
Oslo
Oxford
TOTALS
Zero DR
mismatches
6/7
0/0
2/2
4/4
12/13
92%
Ρ
One DR
mismatch
Grafts (functionaI6/total)
37/42
22/25
15/24
32/40
106/131
81%
= 0 60 ρ = 0 0002
Two DR
mismatches
18/30
12/23
14/31
27/40
71/124
57%
For references, see van Rood et al (1979)
At 6 months after transplantation
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(Termijtelen et al., 1977), and this could explain the good results in the
//LA-£)i?-identical group.
On the other hand, combinations that are mismatched for one HLA-
DR determinant are always MLC-positive. Why is it then that grafts
mismatched for one HLA-DR antigen do so well? From the point of
immunogenetics, this is of course heresy: a difference of an antigen - Λ
between donor and recipient has always been considered to be dominant Jt
over sharing an antigen, and the first question we have to answer is
whether our observation that a one-DR-mismatched graft does so well is
correct.
Corroboratory evidence was obtained from a study by van Hooff et
al. (1974), who had already shown that matching between unrelated
individuals for an HLA-A and -B antigen combination in strong linkage ;
dysequilibrium with an HLA-DR determinant, such as the HLA-
Al,B8,DRw3 combination, was associated with an improved graft sur-
vival. The percentage of graft survival exceeded that obtained for the
overall survival in patients who were matched for two HLA-A and -B
antigens that were not in linkage dysequilibrium. Thus, in this Situation,
donor and recipient were also matched, although indirectly, for one DR
antigen (and mismatched for the other), and this was associated with
better graft survival. There also exists corroborating evidence that one-
DR-mismatched grafts do well in the parent-child data. They do much
better than those differing by two DR antigens; in fact, in Holland they
do as well as //LA-identical siblings (Persijn, unpublished observations).
Others have made similar observations (Thompson et al., 1977a; Oliver
et al., 1972; Fotino and Allen, 1972; Cochrum et al., 1973; Beizer et al,
1974; Dausset et al., 1974; Dausset and Hors, personal Communications;
Hors et al., 1974; Stenzel et al., 1974; Festenstein et al., 1976).
These observations reinforce our finding that matching for only one
DR determinant can significantly improve graft survival. It is also clear
that the data available are limited and in part retrospective and that
prospective trials are indicated. This will be one of the main topics in the
forthcoming 8th Histocompatibility Workshop. This is especially urgent
because data from Los Angeles (Terasaki) and more recently from
European studies have failed to show a significant improvement of graft
survival in the one-DR-antigen-mismatched group, We cannot yet ex-
clude, of course, the possibility that it is not DR we should match for
but another closely linked locus, e.g., HLA-D. Interracial transplants
will be very useful in evaluating this (Troup et al., 1978).
It should be stressed that with the exception of two individuals, all
the recipients in this study who received a kidney mismatched for one
DR determinant had been transfused. Although this might be an important
prerequisite, confiicting data exist on this point. Swedish workers found v
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that graft survival in parent-child combinations was good only lf the
recipient had been transfused before transplantation (Brynger et al.,
1977). The Dutch data are consistent with this, although a control group
of nontransfused recipients IS lackmg. By contrast, Solheim et al. (1977)
and Opelz and Terasaki (1978) did not find a graft-protecüng effect of
blood transfusions in parent-child combinations, and furthermore Morris
Claims that the beneficial effect of DR matching is most clear in the
nontransfused group (Morris, personal Communications).
In an attempt to clanfy the mechamsm by which matching for one
or two DR determinants overndes the effect of incompatibility for other
anügens, we investigated whether these findings on DR matching and
graft survival had anm vitro correlate. Both MLC tests and cell-mediated
lymphocytotoxicity (CML) tests (after in vitro pnming) were studied.
Lymphocytes were taken from patients 3-18 months after transplanta-
tion, and these were reacted with the splenocytes from their specific
kidney donor, which had been stored in liquid nitrogen. The lymphocytes
of slightly more than half the patients who had functioning grafts had a
negative CML test, while they were reactive with lymphocytes from
random donors. We could actually show that the CML test changed from
positive before transplantation to negative after transplantation (Fig. 6).
Our findings show stnkmg similanty to observations of Thomas et
al. (1977), who studied CML reactivity in parent-child combinations,
and of Womgeit and Pichlmayr (1977), who studied cadavenc-kidney-
transplant recipients. The new data from these longitudinal studies
presented here show that the increment of percentage kill against donor
as measured in CML can be negative a few weeks and not many years
after transplantation. In other words, a decreasing CML may be associ-
ated with good survival and an increasing CML with poor survival.
Although our prelimmary studies suggested that CML nonreactivity
occurred most frequently in the one-DR-mismatched group, our recent,
more extensive, data have failed to confirm this. In other words, CML
nonreactivity and DR matching appear not to be significantly associated.
In summary, the current picture emerges as follows·
1. Matching, for two and for one DR determinant improves graft
survival to about 80% at 1 year. It should be stressed that almost
three fourths of our patients were grafted with a kidney that
carned zero or one HLA-A or-B mismatch only. Our data suggest
that DR matching remforces but does not replace HLA-A and -B
matching.
2. Α fall in donor-specific CML develops in at least half the patients
following transplantation. The ongin of this phenomenon is under
study
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Figure 6 Longitudinal CML study after a planned blood transfusion (V) and kidney
transplantation Top CML reactivity against the specific kidney donor, bottom percentdge
lysis against a control cell The follow-up time in days IS on the abscissa
4. Incompatibihty for Non-HLA Determmants
Incompatibilities for determmants outside HLA will influence graft
survival as well. The first example of this was the deletenous effect of
ABO-blood-group incompatibihty on graft survival (Starzl et al , 1964).
More recently, French workers have noticed that kidneys transplanted
in Lewis-blood-group-negative recipients have a poorer prognosis than
Lewis-positive recipients, presumably because of incompatibihty for the
Lewis system (Οποί et al , 1978) This observation could explain why
grafts from Cauca»oid donors, who have a high frequency of Lewis-
positive individuals, do so poorly lf transplanted in patients of negroid
descent, who are often Lewis-negative
Very little attention has so far been paid to cell- or tissue-hne-
specific Systems outside that of the HLA-DR antigens. However, Moraes
and Stastny (1977) have ldentified a multiallelic system that occurs on
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both endothelial cells and monocytes (Table 2). Paul et al. (1979) and
Claas et al. (1979) have independently identified similar antibodies and
have shown that these play in all probability an important role in rejection
of both kidneys (Table 3) and bone-marrow grafts (Table 4). Little is yet
known of the precise conditions under which these antibodies can be
formed, but they can arise after repeated transfusions or kidney-graft
rejection, or both. It is also uncertain whether the locus or loci coding
for the determinants recognized by them lie in or near the HLA complex,
but Thompson et al. (1977b) have identified a polymorphic locus not
linked to HLA coding for determinants on monocytes, endothelial cells,
and neutrophils. Now that the technical difficulties originally met in the
recognition of the monocyte antigens have been solved and their clinical
relevance has been established, it will not take long before a more
complete description of the system will be possible.
Another point that has to be taken into account is that of MHC
restriction, which is dealt with more fully in Chapter 3. In brief, MHC
restriction implies that incompatibility for a non-MHC determinant will
be recognized by the recipient only if donor and recipient share at least
part of the HLA-Α and -B determinants. To describe this, the term "dual
recognition" was coined, by which is meant that both the non-MHC
determinant and the seif HLA-A or -B antigens have to be recognized on
the target cell (Zinkernagel and Doherty, 1974; Shearer, 1974). The dual-
recognition phenomenon was first described in the mouse, but it has also
been shown to exist in man. The non-MHC determinants concern both
intrinsic determinants such as H-Y and extrinsic or acquired antigens
such as those of choriomeningitis or influenza virus.
MHC-restricted immunity against H-Y has been shown in the mouse
TABLE 2. Presence of Ε Antigens in
Endothelial (E) Cells and in Adherent Cells
from Peripheral Blooda
Sera tested
Experiment 1
G.B.
R.G.
W.W.
es.
E.W.
V.S.
Results of cytotoxicity tests
Ε cells
50
70
60
75
90
80
Adherent
monocytes
60
80
40
80
70
65
Nonadherent
lymphocytes
10
10
10
10
10
10
From Moraes and Stastny (1977).
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TABLE 3. Incidence of Circulating
Endothelial Antibodies (CEAb) in 97
Consecutive Allograft Recipientsa
CEAb
Clmical results Present Absent
Irreversible vascular 7 5
rejection in less than
50 days
Graft survival for more 2'' 74
than 50 days
Nommmunological failure 0 9
" Adapted from Paul et al. (1979). Two patients are
excluded, one because of ABO incompatibility and
another because donor kidney tissue was not available.
b
 CEAb present dunng rejection episodes.
skin-graft model to be a transplantation barrier of medium strength (von
Boehmer et al., 1977; Hurme et al., 1978). In man, it has been shown
that MHC-restricted anti-H-Y immunity can occur in vivo and in vitro
using an indirect CML assay. It is of interest that so far MHC restriction
has been found only for the HLA-A2 and -B7 antigens, which belong to
the most immunogenic antigens of the HLA System. That this HLA-
restricted anti-H-Y immunity is of clinical importance is not definitively
proven, but suggestive evidence supporting this notion has been pre-
sented for both kidney and bone-marrow allografts (Table 5) (Storb et
al., 1977; Goulmy et al., 1978). So far, such Information is available only
for H-Y in man, but it is likely that this will be true for other non-MHC
determinants as well, as has been discussed by one of us (Bradley and
TABLE 4. Correlation between the
Presence of Antimonocyte Antibodies
in the Serum and Rejection of the
Bone-Marrow Grafta
Rejection
Antimonocyte
antibodies (TCF)"
- 0 11
ρ = 0.02
From Claase/a/. (1979)
(TCf1) Two-color fiuorescence.
2 7 2
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TABLE 5 Two-year Actuanal Cadavenc-Renal-
Graft Survival in Eurotransplant Patients Sex and
HLA-A2 Data for Male Donors and Female
Recipientsa
Leukocyte antibody-positive group
Donor A2-positive A2 negative
Τ ρ
Recipient A2 positive A2-negative
38% 58%
1 96 0 05
Ν = 48» Ν = 50"
Leukocyte-antibody-negijfrve group
57 9% 61 0%
0 24 0 8
Ν = 53" Ν = 53"
From Goulmy et al (1978)
At nsk after 2 years
Festenstein, 1978, Bradley, in prep ). An effect on graft survival of these
non-MHC lncompatibilities will be present only lf donor and recipienl
share at least some of the HLA-A or -B determinants. In other words, IJ
donor and recipient share none of the HLA-A or -B determinants, the
effect of these determinants might be negligible. This could explain why
grafts mismatched for three or four HLA-A and -B antigens sometimes
do relatively well. These individuals, although mismatched for HLA-A
and -B, would suffer no adverse effect from non-HLA incompatibihties
lf these show MHC restnction. In contrast, recipients of giafts wel.
matched for HLA-A and -B would recognize most of the HLA-A- or -B
restncted minor histocompatibility antigens.
All this concerns dual recognition in which a non-MHC and ar
MHC determinant participate. There IS, however, no reason to exclude
the possibihty that dual recognition could also exist between two differen
classes of MHC determinants. Α good case in point is the targets of tht
CML reaction in HLA, the so-called "CD determinants." Prehminarj
studies indicate that these are closely associated with the HLA-A and
Β determinants but not identical to them (Fig. 7). That this is indeed <
case of HLA-B restnction is suggested by the fact that not a singh
positive reaction was found lf neither Bw35 nor Bw53 was present. W(
assume that to recognize these CD determinants, either Bw35 or Bw5
must be present. The MHC-restncted non-HLA determinants have beei
named by Bradley the histocompatibility-associated membrane or (HAM
minor antigens, the MHC-restncted HLA determinants, the HAM majo
antigens (Bradley and Festenstein, 1978).
We have discussed the role of dual recognition in connection witl·
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HLA antigens Cytotoxic effector cells
Panel Bw53- Bw35 Anti-Sl Anti-S2
1 _
2 __
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
43
42
46
46
43
43
8
57
41
34
31
41
40
43
37
39
50
48
46
20
50
- 2
- 2
0
- 1
- 2
7
2
0
2
2
1
2
1
1
~ 2
5
0
1
1
2
7
3
_
-
27
45
24
21
35
23
19
15
28
22
3
1
2
3
30-70 - 0-9 0-5
Figure 7 Non-HLA-B CML kilhng. Cytotoxic effector cells (anti-Sl and anti-S2) were
rajsed in vitro between sibhngs of one family It was expected that these cells would react
with Bw35-positive individuals It turned out that they did so only in part The donors
carrying the determinants recognized by anti-Sl and anti-S2 were always Bw35- and/or
Bw53-positive, but the patterns of reactivity obtained with the cytotoxic cells were not
identical with the serologically recognized Bw35 and Bw53 or any other HLA antigen. The
lymphocytes of donors who were negative for the Bw35 and/or Bw53 antigens were not
lysed.
the HAM minor and major antigens so far only in relation to the effector
phase of the homograft response. That IS the only part for which some
limited evidence is available.
MHC-restricted immunity against non-HLA and HLA determinants
does not occur spontaneously; in other words, it must be induced in
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vivo. Almost no systematic Information is available on the conditions
under which MHC-restricted immunity can arise, but it is assumed that
this Stimulus must be strong; i.e., it will occur only after many blood
transfusions or graft rejection, or both. In practice, this means that
MHC-restricted immunity will arise only when the recipient is repeatedly
challenged with MHC and non-MHC incompatibilities, in which the
MHC incompatibilities provide "help" for the recognition of the non-
MHC incompatibilities.
5. Discussion and Conclusions
We certainly have not been able to give an all-encompassing answer
to the question why some poorly matched kidneys survive so well, but
we have made a preliminary inventorying of the different factors other
than HLA-A and -B matching that (might) influence graft survival.
In our opinion, blood transfusion is one of the prime variables. Ever
after a Single pretransplant blood transfusion, the homograft reactior
seems to be significantly weakened. The mechanism by which this occur«
is unclear, but could be due to the induction of an (aspecific?) suppresso
cell (Thomas et al., 1977) or to the activation of cell clones that an
capable of forming enhancing antibodies, or to both. On first sight, i
might seem improbable that a Single blood transfusion would be capabk
of inducing antibodies that would be able to enhance the survival ο
kidney grafts from almost any donor. Immunization against the deter
minants of a Single locus, e.g., HLA-DR, is incompatible with th<
induction of such broad-reactive enhancing antibodies (van Rood et al.
1979). However, if we take the MLC Inhibition test as an in vitn
analogue of in vivo enhancement, then a possible explanation offers itsel
(Albert, personal communication; Bach, personal communication). Jon
ker and van Rood (1978) and Albrechtsen et al. (1977) have shown tha
not only anti-DR but also anti-HLA-A and -B antibodies can inhibit th
MLC reaction. The question then becomes what the chance is that
blood-transfusion donor will differ for one of the HLA-A, -B, -C, or -DJ
antigens with the recipient, while sharing it with the kidney donoi
Assuming that cross-reacting antigens can be counted as one, then it ca
be calculated that in about 75% of the recipients of one blood transfusior
the blood-transfusion donor will share a cross-reacting HLA-A, -B, or
DR antigen with the kidney donor, while this antigen is absent in th
recipient. This percentage of "enhanced" grafts can be added to th
20-30% of the grafts that do well even if no blood transfusion is give
and would then result in the high percentage of well-functioning grafi
we have indeed found. This hypothesis is open to experimental proo
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because one would expect that such antibodies would be detectable. We
have not been able to demonstrate their presence with the complement-
dependent cytotoxicity test, but because more sensitive test Systems
have not yet been tried, their existence cannot be formally excluded.
If only one blood transfusion is given, we assume, but again have no / %
hard data to evidence, that immunization against MHC-dependent or ' -~ Jt
independent non-HLA antigens will not frequently occur. There are as
yet insufficient data to assess the importance of (partial) matching for
HLA-DR in the nontransfused patient or after only one blood transfusion. -——
If, on the other hand, many blood transfusions have been given
before transplantation, immunity against HLA and non-HLA determi-
nants will often ensue, and depending on the match of donor and 1
recipient, this will influence graft survival. In our patient material, partial
matching for HLA-DR improves graft survival significantly in this group
of patients. CML nonreactivity can develop in a period of weeks
posttransplantation independently of the DR match. This CML nonreac-
tivity might be due to the induction of suppressor cells or clonal
inactivation or both.
Many of the still-existing discrepancies might disappear if füll char-
acterization of the antibodies formed after blood transfusion were carried
out routinely. This can be quite difficult and is certainly not possible if
only a Standard complement-dependent cytotoxicity test is used. It is
depressing to come to the conclusion that more than 20 years after it was
shown that non-complement-binding antibodies can cause enhancement
instead of graft rejection, almost all centers study their patients' sera
only with complement-dependent cytotoxicity assays. Α complete anal-
ysis of the methods that should be used to detect antibodies in the sera
of transplant recipients and to determine their specificity has yet to be
made. Such an analysis will, apart from the technical problems, also be
hindered by our incomplete knowledge of the immunogenetics of the
HLA and especially the non-HLA Systems. Α beginning of the invento-
rying of the non-HLA Systems that are relevant in kidney transplantation
and the way they exert their influence has been made. It should be
stressed that it is so far only a beginning.
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